Key Highlights
● Aspen priced its IPO at $15, the bottom of its $15 to $17 range.
● The company sold 9.375 million shares, raising about $140.6 million.
● Bambusa Therapeutics priced mid-range at $16 and upsized its deal the same night.
● Investors will watch the opening trade against the $15 offer price.
Aspen Neuroscience (NASDAQ:ASPE), a San Diego biotech developing a stem cell therapy for Parkinson's disease, priced its initial public offering on Thursday night at $15 a share, the bottom of its $15 to $17 range. According to IPO data, the company sold 9.375 million shares, raising about $140.6 million, and the stock is expected to begin trading on Nasdaq under the ticker ASPE on Friday, Oct. 30.
Priced at the floor
The deal was marketed at 9.4 million shares and roughly $150 million, per one IPO calendar, so the final proceeds came in below the headline target because of the lower price rather than a cut in share count. Leerink Partners and Piper Sandler led the offering.
IPO data describes the company as "developing a stem cell therapy to treat patients with Parkinson's Disease." Detailed pipeline and trial timing information was not available in the calendar sources reviewed.
A split verdict as health care rallies
Aspen's pricing stands in contrast with Bambusa Therapeutics, a bispecific antibody developer that priced the same night at $16, the middle of its range, and sold about 10.6 million shares versus 9.4 million originally marketed. Fintech OPay also priced at the low end, at $19.
Why investors pushed Aspen to the floor has not been explained by the company or its bankers. A plausible reading, which is an inference, is that buyers are discriminating between modalities: cell therapies for neurological disease generally involve long development timelines, complex Manufacturing and higher clinical risk than antibody programs.
The pricing also arrived on a tense night for markets. Amazon (NASDAQ:AMZN) and Intel (NASDAQ:INTC) reported after Thursday's close, and by about 8 a.m. ET Friday Nasdaq-100 futures were down roughly 2.6% and S&P 500 futures about 1.1%, according to market data. Russell 2000 futures, a proxy for small caps, were off about 0.6%.
There is a supportive backdrop for health care. The sector gained about 2.4% on Thursday to a record high, according to market reports, led by Eli Lilly (NYSE:LLY)'s raised outlook, and health care ETF XLV was up about 1.2% premarket Friday, per one market note. Treasury yields have also eased, with the 10-year near 4.94% to 4.99% after topping 5.30% earlier this month.
Even so, pricing at the bottom of the range suggests that broader enthusiasm for health care has not translated into aggressive bids for every new issuer. Low-end pricing can sometimes set a stock up for a firmer debut, since the bar is lower, but it can also reflect limited Demand that shows up again once trading begins.
Risks and what to watch
Clinical-stage companies with no approved products depend on trial results, regulatory decisions and future financing. Cell therapies in particular can face manufacturing scale-up challenges and lengthy timelines, any of which could lead to further Capital raises that dilute shareholders.
Macro risk is also elevated. The Federal Reserve held rates this week after a September hike, with markets pricing about 85% odds of a December increase, according to market reports. The VIX was indicated near 18.6 premarket, up from 17.20 at Thursday's close.
Investors will watch Aspen's opening trade relative to the $15 offer price, and whether underwriters need to support the stock. A comparison with Bambusa's debut on the same day will offer a real-time read on which biotech stories the market is willing to pay for.
Further out, attention turns to next week's catalysts: the Nov. 3 midterm elections, the Nov. 6 jobs report, and Anthropic's planned mid-November IPO, which IPO market data estimates at about $75 billion and which could pull capital and attention across the new-issue market.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...